TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00923273

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid tablets
Description: 1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid tablets
Description: 1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid tablets
Description: 1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Description: 4 mg dose twice daily the day before, the day of, and the day after pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Description: 4 mg dose twice daily the day before, the day of, and the day after pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Description: 4 mg dose twice daily the day before, the day of, and the day after pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Description: 4 mg dose twice daily the day before, the day of, and the day after pemetrexed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone tablets
Description: 4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
Study: NCT02778425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: beta blockers
Description: A standard dose of NSBB (propranolol) was applied to the primary prevention patients according to the Baveno VI recommendations if there were no contraindications.
Study: NCT01035983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Study: NCT02678650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volatile anesthetics(isoflurane)
Description: volatile anesthetics wash-in / wash-out operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol intravenous anesthesia
Description: propofol infusion 3-5μg / kg / h
Study: NCT02778425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy
Description: Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy+ PSE
Description: Endoscopic variceal ligation (EVL) is for the primary prophylaxis of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Somatostatin+Endoscopic therapy
Description: The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Somatostatin+Endoscopic therapy+PSE
Description: The first dose of 250 was injected intravenously, followed by a continuous iv infusion of 250 for 3-5 days. Endoscopic variceal ligation (EVL) is for the acute bleeding of esophageal variceal hemorrhage,and Cyanoacrylate injection is for gastric varices (GV).Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches to embolize 60-80% splenic blood flow.
Study: NCT02373891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfolase CR
Description: T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfolase CR
Description: T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
Study: NCT04412668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efzofitimod 1 mg/kg
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efzofitimod 3 mg/kg
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Concentrate for solution for infusion
Study: NCT04258904

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Skin Care Program
Description: The intervention consists of a Skin Care Program including neat information regarding dermatological complications to the device use, prevention of these and moisturizer to keep healthy skin.
Study: NCT03832816

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vapor (distilled water)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized THC alone
Description: Acute exposure to vaporized THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized CBD alone
Description: Acute exposure to vaporized CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized CBD alone
Description: Acute exposure to vaporized CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized CBD alone
Description: Acute exposure to vaporized CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized CBD with THC
Description: Acute exposure to vaporized CBD with THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized CBD with THC
Description: Acute exposure to vaporized CBD with THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized CBD with THC
Description: Acute exposure to vaporized CBD with THC
Study: NCT03502941

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6.3 g of EAAs mixture and whey protein isolate
Description: A single dose of the mixture of EAAs/whey

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12.6 g of EAAs mixture and whey protein isolate
Description: A double dose of the mixture of EAAs/whey

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 12.6 g of whey protein isolate
Description: Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey
Study: NCT01810289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: START
Description: INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level \< 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.~This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design.
Study: NCT00128362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radio-guided sentinel node biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary sampling
Study: NCT01351714

Intervention type: PROCEDURE
Group type: OTHER
Intervention: D3 resection
Description: Radical D3 resection of the right colon through the use of preoperative MDCT angiography
Study: NCT03898752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3
Description: Omega 3: 1g daily for 3 months CoQ10: 100 mg daily for 3 months Multivitamin: 1 normal multivitamin tablet daily for 3 months
Study: NCT01228838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGX-1998
Description: Capsaicin topical liquid to be applied for 5 minutes one time only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGX-1998
Description: Capsaicin topical liquid to be applied for 5 minutes one time only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Liquid
Description: Placebo topical liquid to be applied for 5 minutes one time only.
Study: NCT03290703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants will receive different formulations of GDC-0853 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants will receive different formulations of GDC-0853 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants will receive different formulations of GDC-0853 tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
Study: NCT02437721

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant formula containing folic acid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infant formula containing MTHF
Study: NCT00949949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT03290703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
Study: NCT00949949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT04530708

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: 36 Gy to the primary lung tumor and present mediastinal node metastases after three months of medical treatment.
Study: NCT02731846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg + Vilanterol 25 mcg
Description: Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg + Vilanterol 25 mcg
Description: Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
Study: NCT04235478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Product: triamcinolone and saline
Description: a mixture of 3 mL 0.09%saline and 2 mL 80 mg triamcinolone (kenacort-a)
Study: NCT05812456

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Estimation of Shear Bond Strength
Description: Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Estimation of Shear Bond Strength
Description: Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Estimation of Shear Bond Strength
Description: Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Estimation of Shear Bond Strength
Description: Measuring shear bond strength between the different bracket brands and the enamel will be estimated by aiming the edge of the blade of the universal testing machine at bracket-enamel interface. The force required to debond each bracket will be registered in Newtons (N), and converted to Megapascals by dividing the force registered in newtons on each bracket base area (mm2).~After bond failure, the brackets and the enamel surfaces will be examined and assessed for the amount of adhesive remaining on the bracket bases by using digital microscope at 35x magnification. this will identify the site of bond failure.
Study: NCT02539121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture needles
Study: NCT03097094

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Male dog
Description: Male dog extract

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Female dog
Description: Female dog extract
Study: NCT00352560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Tablets, Oral, 300 mg, once daily, 30 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, 30 days.
Study: NCT01314573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint interval exercise
Description: 3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal continuous exercise
Description: 3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
Study: NCT01954550

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Description: An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Range of motion/stretching exercise
Description: An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
Study: NCT00748501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB-509
Description: Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SB-509
Description: Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
Study: NCT02339272

Intervention type: OTHER
Intervention: non interventional

Intervention type: OTHER
Intervention: non interventional
Study: NCT03766633

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver volumetry of the graft on CT
Description: Preoperative liver volumetry using the CT images of the potential living liver donors.
Study: NCT01673867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Study: NCT02559193

Intervention type: OTHER
Intervention: Observational study, data collection only trial.
Description: Data collection only trial design.
Study: NCT04593225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + multicomponent treatment VIRTUAL SFCAMINA
Description: Group treatment protocol of 12 weekly 60 minute virtual sessions. All sessions include the following ingredients (approx. in the same order): - Pain neuroscience education (15 min.) - Cognitive restructuring (15 min.) - Mindfulness techniques (15 min.) - Physical exercise(15 min.) - Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with SFC.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment-as-Usual (TAU) consisted of the prescribed drugs adapted to the symptomatic profile of each patient and basic face to face and written advice on PNE and aerobic exercise adapted to the physical capacities of the patients at the beginning of the study.
Study: NCT01473836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone sodium
Description: Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
Study: NCT03875885

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CONNECT
Description: A novel web-based intervention with input from an advisory panel of cancer caregivers, oncology providers, and psychosocial oncology professionals empowering caregivers with needs to seek services by providing education about the benefits of supportive care resources, systematically identifying their unmet needs, and connecting them with tailored supportive care resources.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CONTROL
Description: This group will receive a generic resource list. The generic resource list will be printed for participants and emailed to them, if participants have an email address.
Study: NCT04043260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advisor Pro
Description: The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
Study: NCT02048891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist trigger

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG trigger
Study: NCT03558776

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: linseed oil
Description: linseed oil and defined background diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: linseed oil
Description: linseed oil and defined background diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: linseed oil
Description: linseed oil and defined background diet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: linseed oil
Description: linseed oil and defined background diet
Study: NCT01084746

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PC-based tailored intervention
Description: Patients will receive a tailored interactive PC-based intervention at a freestanding kiosk.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed educational materials
Description: Patients will receive generic printed educational materials about CRCS in the PEC when they arrive at the Main Campus for their appointment.
Study: NCT04402931

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcatheter Valve-in-Valve Intervention
Description: Transcatheter mitral valve-in-valve implantation with SAPIEN 3

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Redo Mitral valve surgery
Description: Transcatheter Valve-in-Valve Intervention
Study: NCT00643227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin extended release (ER)
Description: 7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin SR
Description: Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
Study: NCT03069807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community/Primary Care
Description: The treatment of Latent Tuberculosis Infection (LTBI) in the community by General Practitioners (Family Doctors) and Pharmacists

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital/TB Clinic
Description: The treatment of Latent Tuberculosis Infection (LTBI) in the Hospital TB Clinic by specialist doctors and nurses
Study: NCT03894553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Neuro
Description: Unilateral stereotactic focused ultrasound lesioning of the contralateral mesencephalon
Study: NCT01191229

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Tecnis one-piece MF IOL
Description: 25 patients to be implanted after cataract surgery

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Crystalens AO
Description: 25 patients that are previously implanted
Study: NCT03539471

Intervention type: DIAGNOSTIC_TEST
Intervention: interview, Tridimensional Personality Questionnaire
Description: interview of the residents about 15-20 minutes, then use Tridimensional Personality Questionnaire